Iket Injection contains Ketamine at a concentration of 50 mg/ml, a dissociative anesthetic agent widely used in medical practice for induction and maintenance of anesthesia. Ketamine acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, producing analgesia, sedation, and amnesia while maintaining cardiovascular stability and respiratory drive. Iket Injection is indicated for use in diagnostic and surgical procedures requiring anesthesia, particularly in patients where preservation of airway reflexes and spontaneous respiration is desired. It is also employed in emergency settings for rapid sequence intubation and pain management. The onset of action is rapid, with effects typically observed within minutes following intravenous administration. Dosage should be individualized based on patient weight, clinical condition, and procedural requirements, with careful monitoring of vital signs throughout administration. Common adverse effects include transient increases in blood pressure and heart rate, emergence reactions such as vivid dreams or hallucinations, and increased salivation. Caution is advised in patients with cardiovascular disease, elevated intracranial pressure, or psychiatric disorders. Iket Injection should be administered by trained healthcare professionals in a controlled environment equipped for airway management and resuscitation.